AbCellera Biologics (ABCL) Financials

$1.99 -0.10 (-4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.01 (+0.55%)

As of 05:58 PM Eastern

Annual Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-163	-146	159
Consolidated Net Income / (Loss)	-163	-146	159
Net Income / (Loss) Continuing Operations	-163	-146	159
Total Pre-Tax Income	-200	-174	239
Total Operating Income	-315	-237	217
Total Gross Profit	29	38	485
Total Revenue	29	38	485
Operating Revenue	29	38	485
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	344	275	269
Selling, General & Admin Expense	73	61	55
Marketing Expense	13	14	11
Research & Development Expense	167	176	108
Depreciation Expense	91	24	28
Other Operating Expenses / (Income)	0.00	0.00	66
Total Other Income / (Expense), net	114	63	23
Interest & Investment Income	38	42	16
Other Income / (Expense), net	76	21	6.51
Income Tax Expense	-38	-28	81
Basic Earnings per Share	($0.55)	($0.51)	$0.56
Weighted Average Basic Shares Outstanding	294.33M	289.17M	285.06M
Diluted Earnings per Share	($0.55)	($0.51)	$0.50
Weighted Average Diluted Shares Outstanding	294.33M	289.17M	314.83M
Weighted Average Basic & Diluted Shares Outstanding	297.99M	292.78M	287.69M

This table shows AbCellera Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-35	-50	-37	-41	-48	-28	-30	-40	-30	27
Consolidated Net Income / (Loss)	-34	-51	-37	-41	-47	-29	-31	-40	-30	27
Net Income / (Loss) Continuing Operations	-34	-51	-37	-41	-47	-29	-31	-40	-30	27
Total Pre-Tax Income	-47	-63	-48	-43	-49	-39	-38	-48	-31	47
Total Operating Income	-73	-94	-93	-55	-66	-55	-51	-65	-38	38
Total Gross Profit	5.05	6.51	7.32	9.95	9.18	6.60	10	12	22	101
Total Revenue	5.05	6.51	7.32	9.95	9.18	6.60	10	12	22	101
Operating Revenue	5.05	6.51	7.32	9.95	9.18	6.60	10	12	22	101
Total Operating Expenses	78	100	101	65	75	61	61	77	59	64
Selling, General & Admin Expense	16	19	20	17	16	14	16	15	13	14
Marketing Expense	3.14	3.14	3.14	3.37	3.10	3.47	3.84	3.77	2.69	3.09
Research & Development Expense	46	41	41	39	49	38	36	53	28	27
Depreciation Expense	13	37	37	4.84	7.54	5.74	5.61	5.51	14	5.15
Total Other Income / (Expense), net	26	31	45	12	17	16	13	17	6.37	8.85
Interest & Investment Income	8.67	9.60	9.80	10	11	11	11	9.76	8.44	5.56
Other Income / (Expense), net	17	21	35	1.75	6.48	4.87	2.61	6.97	-2.08	3.30
Income Tax Expense	-13	-12	-11	-2.14	-1.45	-11	-7.48	-8.04	-1.52	20
Basic Earnings per Share	($0.11)	($0.17)	($0.13)	($0.14)	($0.16)	($0.10)	($0.11)	($0.14)	($0.10)	$0.09
Weighted Average Basic Shares Outstanding	294.33M	294.85M	294.22M	292.72M	289.17M	289.50M	288.91M	287.77M	285.06M	285.32M
Diluted Earnings per Share	($0.11)	($0.17)	($0.13)	($0.14)	($0.16)	($0.10)	($0.11)	($0.14)	($0.10)	$0.08
Weighted Average Diluted Shares Outstanding	294.33M	294.85M	294.22M	292.72M	289.17M	289.50M	288.91M	287.77M	314.83M	315.82M
Weighted Average Basic & Diluted Shares Outstanding	297.99M	295.37M	294.67M	294.05M	292.78M	290.17M	289.36M	288.73M	287.69M	286.10M

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	23	-254	-86
Net Cash From Operating Activities	-109	-44	277
Net Cash From Continuing Operating Activities	-109	-44	277
Net Income / (Loss) Continuing Operations	-163	-146	159
Consolidated Net Income / (Loss)	-163	-146	159
Depreciation Expense	13	13	8.95
Amortization Expense	84	18	24
Non-Cash Adjustments To Reconcile Net Income	-17	58	56
Changes in Operating Assets and Liabilities, net	-26	13	30
Net Cash From Investing Activities	121	-221	-353
Net Cash From Continuing Investing Activities	121	-221	-353
Purchase of Property, Plant & Equipment	-78	-77	-71
Acquisitions	-20	-14	-28
Purchase of Investments	-754	-1,066	-781
Sale and/or Maturity of Investments	938	911	511
Other Investing Activities, net	36	25	16
Net Cash From Financing Activities	13	10	-1.63
Net Cash From Continuing Financing Activities	13	10	-1.63
Other Financing Activities, net	13	10	-1.63
Effect of Exchange Rate Changes	-2.62	0.59	-9.60

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	30	-22	25	-9.75	-39	-7.33	-13	-194	15	-417
Net Cash From Operating Activities	-8.00	-29	-30	-42	-20	-0.11	20	-44	31	-127
Net Cash From Continuing Operating Activities	-8.00	-29	-30	-42	-20	-0.11	20	-44	31	-127
Net Income / (Loss) Continuing Operations	-34	-51	-37	-41	-47	-29	-31	-40	-30	27
Consolidated Net Income / (Loss)	-34	-51	-37	-41	-47	-29	-31	-40	-30	27
Depreciation Expense	2.10	3.83	3.45	3.16	3.88	3.06	2.95	2.86	2.74	2.53
Amortization Expense	12	34	35	3.61	5.23	4.35	4.30	4.26	13	4.20
Non-Cash Adjustments To Reconcile Net Income	-20	7.55	-23	19	11	20	16	12	16	15
Changes in Operating Assets and Liabilities, net	33	-24	-8.04	-27	7.76	0.80	28	-23	29	-175
Net Cash From Investing Activities	36	3.70	52	30	-24	-13	-34	-150	-17	-282
Net Cash From Continuing Investing Activities	36	3.70	52	30	-24	-13	-34	-150	-17	-282
Purchase of Property, Plant & Equipment	-16	-19	-20	-24	-14	-20	-27	-15	-12	-13
Acquisitions	-1.67	-7.14	-4.91	-5.91	-4.04	-3.54	-2.20	-4.47	-5.91	-6.08
Purchase of Investments	-155	-177	-168	-254	-284	-216	-170	-395	-94	-542
Sale and/or Maturity of Investments	202	197	233	307	268	220	160	263	92	272
Other Investing Activities, net	6.56	9.40	13	7.17	10	7.33	5.00	2.69	2.33	6.00
Net Cash From Financing Activities	4.14	3.15	2.65	2.83	3.77	6.63	0.42	-0.46	0.35	-0.02
Net Cash From Continuing Financing Activities	4.14	3.15	2.65	2.83	3.77	6.63	0.42	-0.46	0.35	-0.02
Other Financing Activities, net	12	0.04	0.28	0.71	10	0.07	0.42	-0.46	2.76	-0.25
Effect of Exchange Rate Changes	-2.16	0.37	-0.04	-0.78	1.07	-1.06	0.80	-0.21	0.36	-8.55

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,361	1,488	1,541
Total Current Assets	751	872	1,025
Cash & Equivalents	156	133	387
Restricted Cash	25	25	25
Short-Term Investments	469	627	500
Accounts Receivable	34	31	39
Other Current Assets	67	56	75
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	609	616	515
Long-Term Investments	82	66	73
Goodwill	48	48	48
Intangible Assets	42	120	132
Other Noncurrent Operating Assets	437	382	264
Total Liabilities & Shareholders' Equity	1,361	1,488	1,541
Total Liabilities	304	336	308
Total Current Liabilities	77	119	118
Short-Term Debt	8.09	50	44
Accounts Payable	55	50	52
Current Deferred Revenue	14	19	22
Total Noncurrent Liabilities	228	217	189
Noncurrent Deferred Revenue	5.70	8.20	20
Noncurrent Deferred & Payable Income Tax Liabilities	10	31	33
Other Noncurrent Operating Liabilities	212	178	137
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,056	1,152	1,233
Total Preferred & Common Equity	1,056	1,152	1,233
Total Common Equity	1,056	1,152	1,233
Common Stock	944	874	808
Retained Earnings	117	280	426
Accumulated Other Comprehensive Income / (Loss)	-4.38	-1.72	-1.39

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,393	1,412	1,463	1,512	1,537	1,498	1,552
Total Current Assets	743	772	814	920	931	941	1,046
Cash & Equivalents	127	148	124	172	180	193	372
Restricted Cash	25	25	25	25	25	25	25
Short-Term Investments	516	522	574	613	616	603	496
Accounts Receivable	31	36	34	37	46	20	106
Other Current Assets	43	40	57	71	64	99	46
Plant, Property, & Equipment, net	0.00	0.00	0.00	277	260	233	201
Total Noncurrent Assets	650	641	649	315	347	324	306
Long-Term Investments	84	76	72	63	59	58	67
Goodwill	48	48	48	48	48	48	48
Intangible Assets	53	86	119	124	127	129	143
Other Noncurrent Operating Assets	465	431	411	81	113	90	49
Total Liabilities & Shareholders' Equity	1,393	1,412	1,463	1,512	1,537	1,498	1,552
Total Liabilities	315	302	333	329	342	289	302
Total Current Liabilities	80	70	105	110	119	90	106
Short-Term Debt	20	20	51	54	55	43	33
Accounts Payable	54	44	43	36	52	32	26
Current Deferred Revenue	5.58	6.40	11	18	8.54	12	6.82
Total Noncurrent Liabilities	235	231	228	219	223	200	196
Noncurrent Deferred Revenue	8.10	7.97	8.57	16	28	25	-
Noncurrent Deferred & Payable Income Tax Liabilities	13	22	30	33	33	33	34
Other Noncurrent Operating Liabilities	214	201	189	170	163	141	162
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,078	1,111	1,130	1,183	1,195	1,209	1,250
Total Preferred & Common Equity	1,078	1,111	1,130	1,183	1,195	1,209	1,250
Total Common Equity	1,078	1,111	1,130	1,183	1,195	1,209	1,250
Common Stock	928	911	893	857	841	824	795
Retained Earnings	151	202	239	327	356	386	456
Accumulated Other Comprehensive Income / (Loss)	-1.23	-2.07	-1.82	-1.46	-1.90	-2.02	-0.72

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-24.17%	-92.17%	29.38%
EBITDA Growth	23.47%	-172.38%	9.89%
EBIT Growth	-10.45%	-196.98%	3.34%
NOPAT Growth	-32.70%	-215.68%	0.28%
Net Income Growth	-11.24%	-192.35%	3.29%
EPS Growth	-7.84%	-202.00%	4.17%
Operating Cash Flow Growth	-147.41%	-115.82%	13.40%
Free Cash Flow Firm Growth	10.50%	-322.85%	-18.56%
Invested Capital Growth	-5.70%	19.69%	17.22%
Revenue Q/Q Growth	-12.53%	-24.54%	-19.52%
EBITDA Q/Q Growth	5.88%	-16.29%	-30.18%
EBIT Q/Q Growth	1.68%	-10.03%	-35.22%
NOPAT Q/Q Growth	-2.18%	-13.53%	-38.85%
Net Income Q/Q Growth	7.36%	-13.36%	-36.17%
EPS Q/Q Growth	8.33%	-13.33%	-37.50%
Operating Cash Flow Q/Q Growth	9.66%	-760.20%	20.73%
Free Cash Flow Firm Q/Q Growth	-0.79%	-20.05%	31.28%
Invested Capital Q/Q Growth	-4.28%	-3.23%	-9.08%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-492.04%	-487.53%	52.76%
Operating Margin	-1,091.69%	-623.82%	44.60%
EBIT Margin	-828.45%	-568.77%	45.94%
Profit (Net Income) Margin	-564.83%	-385.00%	32.66%
Tax Burden Percent	81.27%	84.12%	66.30%
Interest Burden Percent	83.89%	80.47%	107.21%
Effective Tax Rate	0.00%	0.00%	33.70%
Return on Invested Capital (ROIC)	-64.56%	-51.51%	52.79%
ROIC Less NNEP Spread (ROIC-NNEP)	-72.10%	-53.76%	51.04%
Return on Net Nonoperating Assets (RNNOA)	49.82%	39.23%	-38.75%
Return on Equity (ROE)	-14.75%	-12.27%	14.03%
Cash Return on Invested Capital (CROIC)	-58.70%	-69.43%	36.94%
Operating Return on Assets (OROA)	-16.77%	-14.28%	15.60%
Return on Assets (ROA)	-11.43%	-9.67%	11.09%
Return on Common Equity (ROCE)	-14.75%	-12.27%	14.03%
Return on Equity Simple (ROE_SIMPLE)	-15.42%	-12.70%	12.85%
Net Operating Profit after Tax (NOPAT)	-220	-166	144
NOPAT Margin	-764.18%	-436.67%	29.57%
Net Nonoperating Expense Percent (NNEP)	7.53%	2.26%	1.75%
Return On Investment Capital (ROIC_SIMPLE)	-20.71%	-13.80%	11.24%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	252.18%	160.42%	11.43%
R&D to Revenue	580.10%	461.95%	22.22%
Operating Expenses to Revenue	1,191.69%	723.82%	55.40%
Earnings before Interest and Taxes (EBIT)	-239	-216	223
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-142	-185	256
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.82	1.44	2.35
Price to Tangible Book Value (P/TBV)	0.90	1.68	2.75
Price to Revenue (P/Rev)	30.02	43.57	5.97
Price to Earnings (P/E)	0.00	0.00	18.28
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	5.47%
Enterprise Value to Invested Capital (EV/IC)	0.42	2.44	6.67
Enterprise Value to Revenue (EV/Rev)	4.88	22.51	4.03
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	7.65
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	8.78
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	13.64
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	7.06
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	19.50
Leverage & Solvency	-	-	-
Debt to Equity	0.01	0.04	0.04
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.69	-0.73	-0.76
Leverage Ratio	1.29	1.27	1.27
Compound Leverage Factor	1.08	1.02	1.36
Debt to Total Capital	0.76%	4.20%	3.46%
Short-Term Debt to Total Capital	0.76%	4.20%	3.46%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.24%	95.80%	96.54%
Debt to EBITDA	-0.06	-0.27	0.17
Net Debt to EBITDA	5.11	4.32	-3.67
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	-0.04	-0.30	0.31
Net Debt to NOPAT	3.29	4.82	-6.55
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	1.86	3.38	7.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.81	7.33	8.67
Quick Ratio	8.60	6.65	7.82
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-200	-224	100
Operating Cash Flow to CapEx	-138.47%	-57.02%	392.53%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.02	0.03	0.34
Accounts Receivable Turnover	0.90	1.10	4.87
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	406.40	332.04	74.88
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	406.40	332.04	74.88
Capital & Investment Metrics	-	-	-
Invested Capital	331	351	293
Invested Capital Turnover	0.08	0.12	1.79
Increase / (Decrease) in Invested Capital	-20	58	43
Enterprise Value (EV)	141	856	1,958
Market Capitalization	865	1,657	2,898
Book Value per Share	$3.58	$3.97	$4.31
Tangible Book Value per Share	$3.27	$3.39	$3.68
Total Capital	1,064	1,203	1,277
Total Debt	8.09	50	44
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-725	-801	-940
Capital Expenditures (CapEx)	78	77	71
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	18	40
Debt-free Net Working Capital (DFNWC)	683	803	951
Net Working Capital (NWC)	675	753	907
Net Nonoperating Expense (NNE)	-57	-20	-15
Net Nonoperating Obligations (NNO)	-725	-801	-940
Total Depreciation and Amortization (D&A)	97	31	33
Debt-free, Cash-free Net Working Capital to Revenue	111.79%	46.97%	8.22%
Debt-free Net Working Capital to Revenue	2,368.28%	2,112.94%	195.99%
Net Working Capital to Revenue	2,340.23%	1,980.20%	186.88%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.55)	($0.51)	$0.56
Adjusted Weighted Average Basic Shares Outstanding	294.33M	289.17M	285.06M
Adjusted Diluted Earnings per Share	($0.55)	($0.51)	$0.50
Adjusted Weighted Average Diluted Shares Outstanding	294.33M	289.17M	314.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	297.99M	292.78M	287.69M
Normalized Net Operating Profit after Tax (NOPAT)	-220	-166	144
Normalized NOPAT Margin	-764.18%	-436.67%	29.57%
Pre Tax Income Margin	-695.02%	-457.67%	49.26%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-44.99%	-1.39%	-27.18%	-18.36%	-57.40%	-93.49%	-78.10%	-96.15%	-84.54%	1,740.65%
EBITDA Growth	17.57%	20.34%	51.96%	8.67%	-106.01%	-189.21%	-1,738.29%	-121.60%	-128.40%	329.99%
EBIT Growth	6.84%	-44.42%	-18.87%	8.22%	-49.47%	-221.90%	-487.75%	-125.16%	-148.98%	264.31%
NOPAT Growth	-10.14%	-70.64%	-81.86%	15.38%	-74.85%	-278.17%	-512.07%	-127.64%	-145.87%	209.65%
Net Income Growth	27.44%	-78.63%	-20.97%	-1.25%	-57.73%	-207.46%	-349.93%	-123.79%	-149.87%	224.53%
EPS Growth	31.25%	-70.00%	-18.18%	0.00%	-60.00%	-225.00%	-450.00%	-125.93%	-150.00%	200.00%
Operating Cash Flow Growth	59.21%	-27,147.17%	-250.56%	5.34%	-163.44%	99.92%	-92.71%	-143.97%	284.97%	-2,037.32%
Free Cash Flow Firm Growth	70.28%	38.09%	79.87%	-0.41%	-49.57%	42.48%	-6,769.53%	-200.98%	-283.83%	25.80%
Invested Capital Growth	-5.70%	-4.65%	-2.87%	3.88%	19.69%	12.45%	176.24%	1.98%	17.22%	96.18%
Revenue Q/Q Growth	-22.41%	-11.14%	-26.43%	8.46%	39.08%	-34.38%	-17.52%	-43.41%	-78.75%	120.80%
EBITDA Q/Q Growth	-22.56%	-70.12%	56.99%	8.08%	-18.43%	-2.60%	18.23%	-107.34%	-151.29%	2,214.17%
EBIT Q/Q Growth	23.17%	-24.57%	-9.11%	10.78%	-19.10%	-2.53%	15.76%	-45.29%	-197.13%	594.35%
NOPAT Q/Q Growth	22.32%	-0.22%	-70.24%	16.90%	-20.34%	-6.81%	20.79%	-71.72%	-222.63%	466.93%
Net Income Q/Q Growth	33.06%	-38.39%	9.06%	13.87%	-64.80%	6.28%	23.89%	-34.18%	-212.28%	492.40%
EPS Q/Q Growth	35.29%	-30.77%	7.14%	12.50%	-60.00%	9.09%	21.43%	-40.00%	-225.00%	500.00%
Operating Cash Flow Q/Q Growth	72.30%	3.62%	28.15%	-112.68%	-18,400.94%	-100.53%	145.17%	-242.54%	124.38%	-146.44%
Free Cash Flow Firm Q/Q Growth	36.48%	11.14%	-3.63%	49.19%	-32.31%	71.11%	-417.05%	24.31%	49.12%	-3,449.36%
Invested Capital Q/Q Growth	-4.28%	-3.75%	-7.02%	10.09%	-3.23%	-1.96%	-0.56%	26.86%	-9.08%	140.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-823.87%	-521.59%	-272.44%	-465.96%	-549.80%	-645.66%	-412.96%	-416.56%	-113.70%	47.11%
Operating Margin	-1,440.98%	-1,439.42%	-1,276.17%	-551.48%	-719.70%	-831.79%	-511.03%	-532.10%	-175.36%	37.22%
EBIT Margin	-1,099.17%	-1,110.11%	-791.86%	-533.94%	-649.05%	-757.93%	-485.11%	-474.96%	-185.00%	40.47%
Profit (Net Income) Margin	-677.56%	-785.42%	-504.30%	-407.98%	-513.73%	-433.55%	-303.58%	-328.99%	-138.76%	26.26%
Tax Burden Percent	73.05%	81.60%	76.64%	95.00%	97.01%	72.84%	80.33%	83.31%	95.17%	57.15%
Interest Burden Percent	84.38%	86.71%	83.10%	80.43%	81.59%	78.53%	77.90%	83.15%	78.81%	113.54%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	42.85%
Return on Invested Capital (ROIC)	-85.22%	-93.68%	-80.92%	-36.40%	-59.42%	-85.57%	-205.98%	-182.89%	-219.13%	52.66%
ROIC Less NNEP Spread (ROIC-NNEP)	-87.41%	-95.54%	-84.54%	-36.13%	-59.32%	-86.69%	-206.56%	-183.53%	-218.73%	52.07%
Return on Net Nonoperating Assets (RNNOA)	60.40%	65.58%	57.78%	24.40%	43.29%	62.26%	163.30%	127.51%	166.07%	-40.55%
Return on Equity (ROE)	-24.82%	-28.10%	-23.14%	-12.00%	-16.14%	-23.31%	-42.69%	-55.38%	-53.06%	12.10%
Cash Return on Invested Capital (CROIC)	-58.70%	-56.06%	-48.74%	-45.71%	-69.43%	-54.38%	-125.98%	-15.88%	36.94%	31.40%
Operating Return on Assets (OROA)	-22.25%	-25.19%	-17.75%	-12.91%	-16.30%	-24.92%	-44.99%	-55.65%	-62.81%	17.92%
Return on Assets (ROA)	-13.72%	-17.82%	-11.30%	-9.86%	-12.90%	-14.26%	-28.15%	-38.55%	-47.11%	11.63%
Return on Common Equity (ROCE)	-24.82%	-28.10%	-23.14%	-12.00%	-16.14%	-23.31%	-42.69%	-55.38%	-53.06%	12.10%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-16.31%	-13.80%	-13.00%	0.00%	-10.92%	-6.19%	-4.15%	0.00%	19.87%
Net Operating Profit after Tax (NOPAT)	-51	-66	-65	-38	-46	-38	-36	-45	-26	22
NOPAT Margin	-1,008.68%	-1,007.59%	-893.32%	-386.03%	-503.79%	-582.25%	-357.72%	-372.47%	-122.75%	21.27%
Net Nonoperating Expense Percent (NNEP)	2.19%	1.86%	3.62%	-0.28%	-0.10%	1.12%	0.57%	0.63%	-0.40%	0.59%
Return On Investment Capital (ROIC_SIMPLE)	-4.79%	-	-	-	-3.84%	-	-	-	-2.07%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	317.29%	294.25%	275.73%	174.32%	174.06%	217.75%	154.35%	124.13%	60.40%	13.60%
R&D to Revenue	912.58%	629.61%	558.88%	394.69%	529.76%	574.59%	362.70%	431.82%	131.11%	26.22%
Operating Expenses to Revenue	1,540.98%	1,539.42%	1,376.17%	651.48%	819.70%	931.79%	611.03%	632.10%	275.36%	62.78%
Earnings before Interest and Taxes (EBIT)	-55	-72	-58	-53	-60	-50	-49	-58	-40	41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-34	-20	-46	-50	-43	-42	-51	-24	48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.82	0.71	0.78	1.16	1.44	1.13	1.56	1.79	2.35	2.26
Price to Tangible Book Value (P/TBV)	0.90	0.78	0.89	1.36	1.68	1.32	1.83	2.10	2.75	2.66
Price to Revenue (P/Rev)	30.02	23.24	26.33	36.73	43.57	26.41	12.85	11.98	5.97	4.68
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.28	11.35
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.47%	8.81%
Enterprise Value to Invested Capital (EV/IC)	0.42	0.10	0.33	1.48	2.44	1.41	2.81	3.58	6.67	5.86
Enterprise Value to Revenue (EV/Rev)	4.88	1.04	3.60	15.96	22.51	10.15	7.17	7.36	4.03	3.14
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.65	5.16
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.78	5.50
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.64	8.06
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	76.92	0.00	10.02	7.06	8.24
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.50	24.74
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.02	0.02	0.05	0.04	0.05	0.05	0.04	0.04	0.03
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.69	-0.69	-0.68	-0.68	-0.73	-0.72	-0.79	-0.69	-0.76	-0.78
Leverage Ratio	1.29	1.28	1.28	1.27	1.27	1.26	1.30	1.28	1.27	1.24
Compound Leverage Factor	1.09	1.11	1.06	1.02	1.04	0.99	1.01	1.06	1.00	1.40
Debt to Total Capital	0.76%	1.84%	1.77%	4.35%	4.20%	4.36%	4.39%	3.43%	3.46%	2.54%
Short-Term Debt to Total Capital	0.76%	1.84%	1.77%	4.35%	4.20%	4.36%	4.39%	3.43%	3.46%	2.54%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.24%	98.16%	98.23%	95.65%	95.80%	95.64%	95.61%	96.57%	96.54%	97.46%
Debt to EBITDA	-0.06	-0.13	-0.13	-0.28	-0.27	-0.34	-0.79	-1.44	0.17	0.09
Net Debt to EBITDA	5.11	4.86	4.71	4.11	4.32	5.14	11.94	28.08	-3.67	-2.53
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.04	-0.09	-0.11	-0.32	-0.30	-0.37	-0.67	-0.84	0.31	0.14
Net Debt to NOPAT	3.29	3.39	3.99	4.67	4.82	5.61	10.13	16.29	-6.55	-3.95
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.31	2.04	2.42	3.08	3.72	3.29	4.22	5.53	6.98	7.21
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.81	9.34	10.96	7.76	7.33	8.34	7.83	10.50	8.67	9.86
Quick Ratio	8.60	8.48	10.04	6.98	6.65	7.47	7.08	9.11	7.82	9.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-49	-55	-53	-104	-79	-272	-53	-70	-137
Operating Cash Flow to CapEx	-51.18%	-155.98%	-149.01%	-172.78%	-135.89%	-0.52%	73.17%	-294.07%	250.71%	-1,013.23%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.02	0.02	0.02	0.03	0.03	0.09	0.12	0.34	0.44
Accounts Receivable Turnover	0.90	0.96	0.81	1.32	1.10	0.70	2.95	1.02	4.87	8.06
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.21	0.71	1.02	0.00	4.13
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	406.40	381.03	451.76	277.53	332.04	519.40	123.79	357.27	74.88	45.26
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	406.40	381.03	451.76	277.53	332.04	519.40	123.79	357.27	74.88	45.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	331	346	360	387	351	363	370	372	293	323
Invested Capital Turnover	0.08	0.09	0.09	0.09	0.12	0.15	0.58	0.49	1.79	2.48
Increase / (Decrease) in Invested Capital	-20	-17	-11	14	58	40	236	7.23	43	158
Enterprise Value (EV)	141	34	119	571	856	511	1,041	1,333	1,958	1,893
Market Capitalization	865	766	870	1,314	1,657	1,331	1,865	2,169	2,898	2,820
Book Value per Share	$3.58	$3.66	$3.78	$3.86	$3.97	$4.09	$4.14	$4.20	$4.31	$4.38
Tangible Book Value per Share	$3.27	$3.32	$3.32	$3.29	$3.39	$3.49	$3.53	$3.59	$3.68	$3.72
Total Capital	1,064	1,098	1,131	1,181	1,203	1,237	1,250	1,251	1,277	1,283
Total Debt	8.09	20	20	51	50	54	55	43	44	33
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-725	-732	-751	-743	-801	-820	-825	-836	-940	-927
Capital Expenditures (CapEx)	16	19	20	24	14	20	27	15	12	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	15	26	37	18	52	46	72	40	79
Debt-free Net Working Capital (DFNWC)	683	684	721	760	803	863	867	894	951	972
Net Working Capital (NWC)	675	663	701	709	753	809	812	851	907	940
Net Nonoperating Expense (NNE)	-17	-14	-28	2.18	0.91	-9.81	-5.44	-5.30	3.45	-5.06
Net Nonoperating Obligations (NNO)	-725	-732	-751	-743	-801	-820	-825	-836	-940	-927
Total Depreciation and Amortization (D&A)	14	38	38	6.77	9.11	7.41	7.26	7.12	15	6.73
Debt-free, Cash-free Net Working Capital to Revenue	111.79%	46.70%	78.19%	104.71%	46.97%	103.93%	31.69%	40.02%	8.22%	13.09%
Debt-free Net Working Capital to Revenue	2,368.28%	2,073.70%	2,181.89%	2,125.06%	2,112.94%	1,713.05%	597.01%	493.79%	195.99%	161.17%
Net Working Capital to Revenue	2,340.23%	2,012.36%	2,121.30%	1,981.35%	1,980.20%	1,606.03%	559.21%	470.11%	186.88%	155.77%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.11)	($0.17)	($0.13)	($0.14)	($0.16)	($0.10)	($0.11)	($0.14)	($0.10)	$0.09
Adjusted Weighted Average Basic Shares Outstanding	294.33M	294.85M	294.22M	292.72M	289.17M	289.50M	288.91M	287.77M	285.06M	285.32M
Adjusted Diluted Earnings per Share	($0.11)	($0.17)	($0.13)	($0.14)	($0.16)	($0.10)	($0.11)	($0.14)	($0.10)	$0.08
Adjusted Weighted Average Diluted Shares Outstanding	294.33M	294.85M	294.22M	292.72M	289.17M	289.50M	288.91M	287.77M	314.83M	315.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	297.99M	295.37M	294.67M	294.05M	292.78M	290.17M	289.36M	288.73M	287.69M	286.10M
Normalized Net Operating Profit after Tax (NOPAT)	-51	-66	-65	-38	-46	-38	-36	-45	-26	22
Normalized NOPAT Margin	-1,008.68%	-1,007.59%	-893.32%	-386.03%	-503.79%	-582.25%	-357.72%	-372.47%	-122.75%	21.27%
Pre Tax Income Margin	-927.49%	-962.53%	-658.02%	-429.45%	-529.54%	-595.18%	-377.92%	-394.91%	-145.81%	45.95%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AbCellera Biologics' Financials

When does AbCellera Biologics's fiscal year end?

According to the most recent income statement we have on file, AbCellera Biologics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AbCellera Biologics' net income changed over the last 2 years?

AbCellera Biologics' net income appears to be on an upward trend, with a most recent value of -$162.86 million in 2024, falling from $158.52 million in 2022. The previous period was -$146.40 million in 2023. View AbCellera Biologics' forecast to see where analysts expect AbCellera Biologics to go next.

What is AbCellera Biologics's operating income?

AbCellera Biologics's total operating income in 2024 was -$314.77 million, based on the following breakdown:

Total Gross Profit: $28.83 million
Total Operating Expenses: $343.60 million

How has AbCellera Biologics revenue changed over the last 2 years?

Over the last 2 years, AbCellera Biologics' total revenue changed from $485.42 million in 2022 to $28.83 million in 2024, a change of -94.1%.

How much debt does AbCellera Biologics have?

AbCellera Biologics' total liabilities were at $304.47 million at the end of 2024, a 9.3% decrease from 2023, and a 1.0% decrease since 2022.

How much cash does AbCellera Biologics have?

In the past 2 years, AbCellera Biologics' cash and equivalents has ranged from $133.32 million in 2023 to $386.54 million in 2022, and is currently $156.33 million as of their latest financial filing in 2024.

How has AbCellera Biologics' book value per share changed over the last 2 years?

Over the last 2 years, AbCellera Biologics' book value per share changed from 4.31 in 2022 to 3.58 in 2024, a change of -17.1%.

Related Companies

This page (NASDAQ:ABCL) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Financials

Frequently Asked Questions About AbCellera Biologics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Financials

Annual Income Statements for AbCellera Biologics

Quarterly Income Statements for AbCellera Biologics

Annual Cash Flow Statements for AbCellera Biologics

Quarterly Cash Flow Statements for AbCellera Biologics

Annual Balance Sheets for AbCellera Biologics

Quarterly Balance Sheets for AbCellera Biologics

Annual Metrics And Ratios for AbCellera Biologics

Quarterly Metrics And Ratios for AbCellera Biologics

Frequently Asked Questions About AbCellera Biologics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools